Genes Associated with m6A Modifications Indicate Prognostic Risk and Immune Modulation in Lung Adenocarcinoma
-
By
-
Xiaoxing Liu
-
Shanshan Li
-
Min Zhou
-
Ning Ding
-
Jinzhong Chen
-
Ning Zhou
-
January 16, 2026
-
Clinical Scorecard: Genes Associated with m6A Modifications Indicate Prognostic Risk and Immune Modulation in Lung Adenocarcinoma
At a Glance
| Category | Detail |
|---|
| Condition | Lung Adenocarcinoma (LUAD) |
| Key Mechanisms | m6A modification regulates gene expression impacting tumor progression and immune response. |
| Target Population | Patients with lung adenocarcinoma |
| Care Setting | Oncology clinics and research settings |
Key Highlights
- m6A modifications are linked to tumor progression and prognosis in LUAD.
- High-throughput sequencing reveals genetic variations in m6A regulators.
- Aberrant m6A expression affects immune microenvironment and treatment response.
- m6A-based prognostic models may identify biomarkers for LUAD.
- Integration of multi-omics data enhances understanding of LUAD.
Guideline-Based Recommendations
Diagnosis
- Utilize multi-omics data for comprehensive assessment of LUAD.
Management
- Consider m6A modification patterns in therapeutic strategy development.
Monitoring & Follow-up
- Assess immune microenvironment changes in response to treatment.
Risks
- Monitor for immune evasion mechanisms linked to m6A alterations.
Patient & Prescribing Data
Patients diagnosed with lung adenocarcinoma, particularly those with advanced disease.
m6A modifications may guide immunotherapy approaches and prognostic assessments.
Clinical Best Practices
- Incorporate genetic risk models based on m6A-related DEGs for prognosis.
- Utilize bioinformatics techniques to analyze m6A modification impacts.
References
